Literature DB >> 10821438

Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain.

I Kusumi1, Y Takahashi, K Suzuki, K Kameda, T Koyama.   

Abstract

The effects of 3-week treatment with a typical antipsychotic drug chlorpromazine and three atypical antipsychotic drugs (risperidone, olanzapine and perospirone) on the binding to dopamine D2 and serotonin 5-HT2A receptors were examined in the rat stratum and frontal cortex, respectively. Subchronic treatment with chlorpromazine (10 mg/kg) and perospirone (1 mg/kg) significantly increased D2 receptors, while no increase was observed with lower dose of chlorpromazine (5 mg/kg), perospirone (0.1 mg/kg), risperidone (0.25, 0.5 mg/kg) or olanzapine (1, 2 mg/kg). On the other hand, 3-week administration of chlorpromazine (5, 10 mg/kg) and olanzapine (1, 2 mg/kg) significantly decreased 5-HT2A receptors, but risperidone (0.25, 0.5 mg/kg) or perospirone (0.1, 1 mg/kg) had no effect. The measurement of in vivo drug occupation for D2 and 5-HT2A receptors using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) suggested that high occupation of 5-HT2A receptors with lower D2 receptor occupancy might be involved in the absence of up-regulation of D2 receptors after subchronic treatment with some atypical antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821438     DOI: 10.1007/s007020050024

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  12 in total

1.  Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex.

Authors:  N A Muma; R K Singh; M S Vercillo; D N D'Souza; B Zemaitaitis; F Garcia; K J Damjanoska; Y Zhang; G Battaglia; L D Van de Kar
Journal:  Neuropharmacology       Date:  2007-07-01       Impact factor: 5.250

2.  Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.

Authors:  Cüneyt Güzey; Maria Gabriella Scordo; Edoardo Spina; Veslemøy Malm Landsem; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

3.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

4.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

Review 5.  Perospirone.

Authors:  S V Onrust; K McClellan
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

Authors:  James L Roerig; Kristine J Steffen; James E Mitchell
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

7.  Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2008-02-24       Impact factor: 4.530

8.  Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex.

Authors:  Benoit Labonte; Francis Rodriguez Bambico; Gabriella Gobbi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11       Impact factor: 3.000

9.  Antipsychotic Drugs Inhibit Platelet Aggregation via P2Y 1 and P2Y 12 Receptors.

Authors:  Chang-Chieh Wu; Fu-Ming Tsai; Mao-Liang Chen; Semon Wu; Ming-Cheng Lee; Tzung-Chieh Tsai; Lu-Kai Wang; Chun-Hua Wang
Journal:  Biomed Res Int       Date:  2016-03-16       Impact factor: 3.411

10.  Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors.

Authors:  Michael De Santis; Xu-Feng Huang; Chao Deng
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.